Fate Therapeutics Stock Performance
| FATE Stock | USD 3.95 0.09 2.23% |
The firm shows a Beta (market volatility) of -0.0204, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Fate Therapeutics are expected to decrease at a much lower rate. During the bear market, Fate Therapeutics is likely to outperform the market. Fate Therapeutics has an expected return of -0.72%. Please make sure to confirm Fate Therapeutics semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if Fate Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in June 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (2.23) | Five Day Return (4.59) | Year To Date Return 7.05 | Ten Year Return (42.59) | All Time Return (40.33) |
1 | Fate Therapeutics, Inc. Held Back By Insufficient Growth Even After Shares Climb 57 | 02/16/2024 |
2 | Exercise or conversion by Wolchko J Scott of 30000 shares of Fate Therapeutics subject to Rule 16b-3 | 02/26/2024 |
3 | Disposition of 2447 shares by Dulac Edward J Iii of Fate Therapeutics at 7.77 subject to Rule 16b-3 | 03/04/2024 |
4 | Acquisition by Redmile Group, Llc of 3636364 shares of Fate Therapeutics at 0.001 subject to Rule 16b-3 | 03/21/2024 |
5 | Fate Therapeutics Shares Up 5.1 percent - MarketBeat | 03/25/2024 |
6 | Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635 | 04/02/2024 |
7 | Acquisition by Redmile Group, Llc of 8650 shares of Fate Therapeutics subject to Rule 16b-3 | 04/11/2024 |
8 | Fate Therapeutics, Inc. Sees Significant Growth in Short Interest - MarketBeat | 04/15/2024 |
9 | ViewSonic Announces New Partnership with FATE Esports | 04/18/2024 |
10 | Disposition of 3854 shares by Powl Brian T. of Fate Therapeutics at 4.87 subject to Rule 16b-3 | 04/19/2024 |
11 | Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting | 04/22/2024 |
12 | Fate Therapeutics As Its Rally Fizzles, We May Be Near The Bottom - Seeking Alpha | 04/29/2024 |
| Begin Period Cash Flow | 61.3 M |
Fate |
Fate Therapeutics Relative Risk vs. Return Landscape
If you would invest 676.00 in Fate Therapeutics on February 1, 2024 and sell it today you would lose (281.00) from holding Fate Therapeutics or give up 41.57% of portfolio value over 90 days. Fate Therapeutics is currently does not generate positive expected returns and assumes 5.3359% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Fate, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Fate Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fate Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Fate Therapeutics, and traders can use it to determine the average amount a Fate Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1358
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FATE |
Estimated Market Risk
| 5.34 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.72 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.14 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Fate Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fate Therapeutics by adding Fate Therapeutics to a well-diversified portfolio.
Fate Therapeutics Fundamentals Growth
Fate Stock prices reflect investors' perceptions of the future prospects and financial health of Fate Therapeutics, and Fate Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fate Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.53) % | ||||
| Operating Margin | (20.99) % | ||||
| Current Valuation | 189.28 M | ||||
| Shares Outstanding | 113.78 M | ||||
| Price To Earning | (4.35) X | ||||
| Price To Book | 1.79 X | ||||
| Price To Sales | 10.33 X | ||||
| Revenue | 63.53 M | ||||
| Gross Profit | (224.15 M) | ||||
| EBITDA | (159.33 M) | ||||
| Net Income | (160.93 M) | ||||
| Cash And Equivalents | 568.85 M | ||||
| Cash Per Share | 5.86 X | ||||
| Total Debt | 103.54 M | ||||
| Debt To Equity | 0.19 % | ||||
| Current Ratio | 6.55 X | ||||
| Book Value Per Share | 3.73 X | ||||
| Cash Flow From Operations | (132.26 M) | ||||
| Earnings Per Share | (1.64) X | ||||
| Market Capitalization | 459.68 M | ||||
| Total Asset | 506.22 M | ||||
| Retained Earnings | (1.21 B) | ||||
| Working Capital | 292.45 M | ||||
| Current Asset | 47.4 M | ||||
| Current Liabilities | 14.68 M | ||||
About Fate Therapeutics Performance
To evaluate Fate Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Fate Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Fate Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Fate Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Fate's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 0.000024 | 0.000012 | |
| Return On Tangible Assets | (0.32) | (0.33) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.32) | (0.33) | |
| Return On Equity | (0.44) | (0.46) |
Things to note about Fate Therapeutics performance evaluation
Checking the ongoing alerts about Fate Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Fate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fate Therapeutics generated a negative expected return over the last 90 days | |
| Fate Therapeutics has high historical volatility and very poor performance | |
| Fate Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 63.53 M. Net Loss for the year was (160.93 M) with loss before overhead, payroll, taxes, and interest of (224.15 M). | |
| Fate Therapeutics currently holds about 568.85 M in cash with (132.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Fate Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Fate Therapeutics As Its Rally Fizzles, We May Be Near The Bottom - Seeking Alpha |
- Analyzing Fate Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fate Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Fate Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fate Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fate Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fate Therapeutics' stock. These opinions can provide insight into Fate Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Fate Stock analysis
When running Fate Therapeutics' price analysis, check to measure Fate Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fate Therapeutics is operating at the current time. Most of Fate Therapeutics' value examination focuses on studying past and present price action to predict the probability of Fate Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fate Therapeutics' price. Additionally, you may evaluate how the addition of Fate Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |
Is Fate Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.64) | Revenue Per Share 0.646 | Quarterly Revenue Growth (0.96) | Return On Assets (0.18) | Return On Equity (0.38) |
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.